Niciane (Mometasone Furoate Anhydrous)

Mometasone furoate, the active ingredient in Niciane, is a corticosteroid presented as a nasal spray for intranasal use. It is employed to manage inflammatory nasal conditions such as allergic rhinitis and nasal polyps in adults and children as directed by a healthcare professional.

GNH USA supplies Niciane as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mometasone furoate nasal spray is indicated for inflammatory conditions of the nasal passages and sinuses.

- Allergic rhinitis: reduces nasal congestion, itching, sneezing and rhinorrhea. - Nasal polyps (post‑surgical maintenance): helps prevent polyp regrowth and improves nasal airflow. - Non‑allergic rhinitis: alleviates chronic nasal inflammation and related symptoms.

Adverse reactions are generally mild to moderate and related to local nasal exposure.

Common Side Effects: - Nasal irritation or burning sensation. - Epistaxis (nosebleeds). - Headache. - Throat irritation or dryness. - Altered taste or bitter taste. - Cough.

Serious or Rare Side Effects: - Adrenal suppression with prolonged high‑dose use. - Cataracts or glaucoma. - Nasal septal perforation. - Fungal infection of the nasal passages. - Severe or persistent epistaxis. - Systemic immunosuppression leading to infection.

Before initiating therapy, consider patient‑specific factors and proper handling of the product.

- Pregnancy: consult a healthcare provider before use. - Lactation: discuss potential risks with a clinician. - Children: use only as prescribed and monitor growth. - Recent nasal surgery or trauma: avoid until mucosa has healed. - Long‑term use: monitor for signs of systemic corticosteroid effects. - Store at room temperature: keep in the original container, protect from moisture and direct heat.

Mometasone furoate may interact with other medications that affect corticosteroid metabolism or immune function.

Major Interactions (Avoid): - Systemic corticosteroids: may increase systemic glucocorticoid exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can raise local drug levels. - Live vaccines: potential reduced vaccine efficacy.

Moderate Interactions (Monitor Closely): - Antifungal agents (e.g., fluconazole) that modestly inhibit CYP3A4. - Other intranasal medications (decongestants, antihistamines) that may alter absorption. - Immunosuppressive agents: monitor for increased infection risk.